Analystreport

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) had its "market perform" rating re-affirmed by analysts at Roth Capital. They now have a $33.00 price target on the stock.

Galmed Pharmaceuticals Ltd. - Ordinary Shares  (GLMD) 
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: galmedpharma.investorroom.com